Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124,432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1.
Liang F, Wang GZ, Wang Y, Yang YN, Wen ZS, Chen DN, Fang WF, Zhang B, Yang L, Zhang C, Han SC, Yang FY, Wang D, Liang LJ, Wang Z, Zhao Y, Wang CL, Zhang L, Zhou GB. Liang F, et al. Among authors: zhang l, zhang b, zhang c. Signal Transduct Target Ther. 2022 Sep 7;7(1):311. doi: 10.1038/s41392-022-01127-3. Signal Transduct Target Ther. 2022. PMID: 36068203 Free PMC article.
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment.
Duan J, Xu J, Wang Z, Bai H, Cheng Y, An T, Gao H, Wang K, Zhou Q, Hu Y, Song Y, Ding C, Peng F, Liang L, Hu Y, Huang C, Zhou C, Shi Y, Han J, Wang D, Tian Y, Yang Z, Zhang L, Chuai S, Ye J, Zhu G, Zhao J, Wu YL, Wang J. Duan J, et al. Among authors: zhang l. J Thorac Oncol. 2020 Dec;15(12):1857-1870. doi: 10.1016/j.jtho.2020.08.020. Epub 2020 Sep 9. J Thorac Oncol. 2020. PMID: 32916309 Free article.
Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer.
Guan S, Chen X, Xin S, Liu S, Yang Y, Fang W, Huang Y, Zhao H, Zhu X, Zhuang W, Wang F, Feng W, Zhang X, Huang M, Wang X, Zhang L. Guan S, et al. Among authors: zhang l, zhang x. Transl Oncol. 2021 Jan;14(1):100951. doi: 10.1016/j.tranon.2020.100951. Epub 2020 Nov 19. Transl Oncol. 2021. PMID: 33221684 Free PMC article.
Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study.
Zhao S, Zhang Z, Fang W, Zhang Y, Zhang Z, Hong S, Ma Y, Zhou T, Yang Y, Huang Y, Zhao H, Zhang L. Zhao S, et al. Among authors: zhang l, zhang z, zhang y. Front Oncol. 2020 Nov 10;10:587849. doi: 10.3389/fonc.2020.587849. eCollection 2020. Front Oncol. 2020. PMID: 33244458 Free PMC article.
EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.
Bai H, Duan J, Li C, Xie W, Fang W, Xu Y, Wang G, Wan R, Sun J, Xu J, Wang X, Fei K, Zhao Z, Cai S, Zhang L, Wang J, Wang Z. Bai H, et al. Among authors: zhang l. J Immunother Cancer. 2020 Dec;8(2):e001315. doi: 10.1136/jitc-2020-001315. J Immunother Cancer. 2020. PMID: 33303576 Free PMC article.
124,432 results
You have reached the last available page of results. Please see the User Guide for more information.